Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

treated with interferon and ribavirin alone, although conclusions regarding safety cannot be made until results in more patients over longer duration are known.  Positive preliminary SVR data were also presented.
  • AASLD 2010, IL28B Poster data showed that the addition of ANA598 to SOC has the potential to confer beneficial effect on HCV patients regardless of IL-28B genotype.
  • EASL 2010 and ICAR 2010, Preclinical Posters – presented data showing enhanced antiviral activity and suppression of resistance when ANA598 is combined in vitro with other anti-HCV agents that act through diverse mechanisms, including protease inhibition, polymerase inhibition (both nucleoside and non-nucleoside inhibitors) and cyclophilin inhibition (a host target).

  • Conference Call WebcastAnadys will host a conference call at 5:00 pm Eastern Standard Time today to discuss its fourth quarter and year-end 2010 financial results and highlights.  A live webcast of the call, including accompanying slides, will be available online at www.anadyspharma.com.  A telephone replay will also be available approximately one hour after completion of the call.  To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 62030425.  The webcast and telephone replay will be available through March 17, 2011.Condensed Consolidated Financial StatementsAnadys Pharmaceuticals, Inc.Condensed Consolidated Statements of Operations(In thousands except per share amounts)(Unaudited)Three Months EndedDecember 31,Twelve Months EndedDecember 31,2010200920102009Operating expensesResearch and development

    $

    2,753$

    3,948$

    12,026$

    19,494General and administrative1,7271,6326,4788,243Total operating expenses (1)4,4805,58018,50427,737Interest income and other, net2544139610Gain (loss) from valuation of common sto
    '/>"/>

    SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
    2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
    3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
    4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
    5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
    6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
    7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
    8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
    9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
    10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
    11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website that ... used solely in scientific experiments, is currently celebrating its ... business, Maxim Peptide, which was created by the founders ... and updated website that now features a special deals ... updated with fascinating articles about peptide research, including a ...
    (Date:7/11/2014)... 2014 Research and Markets  has announced ... - Global Industry Analysis, Size, Share, Growth, Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection ... DNA or RNA) into cells. This technology helps the ... and protein metabolism by affecting the nuclear genes. The ...
    (Date:7/11/2014)... GENEVA , July 11, 2014 ... pleased to announce the appointment of John P. ... Campus Biotech   in  Geneva . ... on Campus Biotech in Geneva , ... internationally recognised neuroscientists. John P. Donoghue , founder ...
    (Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
    Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3
    ... DIEGO, June 4 Anadys Pharmaceuticals, Inc. (Nasdaq: ... operations on the development of ANA598, in particular a proposed ... combination with pegylated interferon-alpha and ribavirin. , ... suspend further development of ANA773 and is reducing its workforce ...
    ... Push of a Button , , CLEVELAND, June 4 ... the patented probiotic strain Ganeden BC30 (R), today announced a ... beverage using PowerCap(R) technology, the innovative bottle cap dispensing system. ... with the press of a button, creating a new category ...
    ... Roche at 69th Scientific Sessions , , SAN ... VIAP ), a biotechnology company focused on the ... metabolic disease, announced today that preclinical data related to ... presented in a poster presentation at the 69th Scientific ...
    Cached Biology Technology:Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 2Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 3Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 4Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 5Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology 2Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 2VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 4
    (Date:7/10/2014)... , June 27, 2014  The American Academy ... Institute of Standards and Technology (NIST) and the ... academic research and forensic science expert members to ... is an element of the NIST,s Organization of ... among the first appointments made to the new ...
    (Date:7/10/2014)... 30, 2014  Aware, Inc. (NASDAQ: AWRE ... previously announced on June 26, 2014 that its Board ... $1.75 per share, or approximately $40 million in total.  ... 2014 and a payment date of July 24, 2014.  ... had set an ex-dividend date for this special cash ...
    (Date:7/10/2014)... 2014  Unisys Corporation,s (NYSE: UIS ) subsidiary ... today announced that it has been selected by the Dutch ... new Basic Provision Biometrics solution for penitentiaries across ... contract with a solution based on its open standards-based ... the contract is up to seven years, with the new ...
    Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
    ... first time, UK scientists have reported direct evidence that taking ... of cancer. The results were reported at the 35th ... Milan, Italy. The link between smoking and cancer has ... the Cancer Research UK Institute of Cancer Studies, Birmingham, who ...
    ... cancer patients seem to live longer and experience delays in ... molecule called MET is added to treatment with erlotinib, the ... David Spigel, Director of lung cancer research for the Sarah ... at the 35th Congress of the European Society for Medical ...
    ... Researchers at the University of Illinois at Chicago College of ... drug resistance is ramped up in unusual types of breast ... study is published in the Oct. 8 issue of the ... a paper of the week. Approximately 70 percent of ...
    Cached Biology News:Study reveals cancer-linked epigenetic effects of smoking 2New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer 2Clue to unusual drug-resistant breast cancers found 2
    ... Versatile, modular, computer controlled pre-amplifier suitable for ... isolated electrode input for recording physiological signal ... and a transducer input for use with ... transducers. Additional options include a stimulus artefact ...
    SYBR Green Nucleic Acid Dye...
    ... from an inert polymer with a unique split ... split septum caps for use with 384-well tall-chimney ... when used in conjunction with screw or clip-down ... pipetting equipment 384 septum caps may be ...
    ... ion chromatography system . The sensitive conductivity ... to 5000S, houses the measuring cell in a ... is available. Data processing is provided by ... is by the high pressure CE 4100 dual ...
    Biology Products: